First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Public ClinicalTrials.gov record NCT01120457. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and tolerability of BMS-936564 (MDX-1338) in relapsed Acute myelogenous leukemia (AML) and other selected B-cell cancers and to determine the maximum tolerated dose (MTD) of the drug alone in relapsed/refractory AML
Study identification
- NCT ID
- NCT01120457
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 96 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2010
- Primary completion
- Oct 31, 2014
- Completion
- Oct 31, 2014
- Last update posted
- Mar 5, 2015
2010 – 2014
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Uab Comprehensive Cancer Center | Birmingham | Alabama | 35294 | — |
| Uc San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Usc - Norris Comprehensive Cancer Center And Hospital | Los Angeles | California | 90033 | — |
| Ucla-Division Of Hematology/Oncology | Los Angeles | California | 90095 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Northwestern University Feinberg School Of Medicine | Chicago | Illinois | 60611 | — |
| University Of Kansas Cancer Center And Medical Pavillion | Westwood | Kansas | 66205 | — |
| B. Douglas Smith, M.D. | Baltimore | Maryland | 21287 | — |
| Dana-Farber Cancer Inst | Boston | Massachusetts | 02215 | — |
| The University Of Texas Md Anderson Cancer Center | Houston | Texas | 77030 | — |
| University Of Washington School Of Medicine | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01120457, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2015 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01120457 live on ClinicalTrials.gov.